Pfizer stock
Price history
+12.02% over the period1 year: from $25.79 (November 13, 2025) to $28.89 (November 13, 2026), +12.02%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 13, 2026 | $28.89 |
| October 30, 2026 | $30.52 |
| September 30, 2026 | $28.52 |
| August 31, 2026 | $28.46 |
| July 31, 2026 | $25.01 |
| June 30, 2026 | $24.08 |
| May 29, 2026 | $26.18 |
| April 30, 2026 | $26.70 |
| March 31, 2026 | $28.08 |
| February 27, 2026 | $27.65 |
| January 30, 2026 | $26.44 |
| December 31, 2025 | $24.90 |
| November 28, 2025 | $25.74 |
| November 13, 2025 | $25.79 |
At a glance
The company
Discovers, develops, manufactures and sells biopharmaceutical products for internal medicine, inflammation, immunology, rare diseases, anti-infectives and oncology
Latest results
Quarter to September 30, 2026 · EPS $0.87 (estimate $0.73)
Next event
TickerLandia's take on Pfizer
- Priced as usual relative to earnings: P/E on the latest fiscal year 21 vs a median of 19 over its last 10 fiscal years.
- Priced in line with similar companies: trailing 12-month P/E 41 vs 42 (−2%) in a group of 10.
- Strong point: Dividend (94/100 in its group). Weak point: Growth (14/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−8.11% from the 52-week high
Analysts · 28 analysts
Average target$30.22+4.61% vs. price
Buy 9 · Hold 17 · Sell 2 · Buy
TickerLandia Fingerprint: Pfizer
Compared with similar companies: very high dividend, very low growth, and very low risk.
Financials and price compared with 25 companies in the drug manufacturers - general industry, worldwide. Momentum and risk compared with 883 North American stocks.
Pricelow31
How much it costs relative to what it produces.
Metric Value Position in group P/E (trailing 12 months) 41.3 76 Forward P/E 9.80 10 EV/EBITDA 8.59 26 Price/book 1.85 10 Price/sales 2.59 34 Profitabilitylow33
How much it earns on revenue and capital.
Metric Value Position in group Gross margin 74.9% 66 Net margin 6.3% 18 Operating margin 29.1% 46 ROE 4.5% 15 ROA 5.6% 22 Earnings stabilitylow30
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 10.9% 6 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 54 Growthvery low14
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) −14.80% 2 Revenue growth (year over year) −0.40% 6 Earnings growth (year over year) −9.70% 35 Financial strengthlow33
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Net debt/EBITDAcounts in reverse: lower means more financial strength 2.58 14 Interest coverage 7.17 14 Current ratio 1.42 58 Debt/equitycounts in reverse: lower means more financial strength 0.71 48 Dividendvery high94
How much it returns to shareholders, and for how long.
Metric Value Position in group Consecutive dividend years at least 37 years 90 Dividend yield 6.0% 98 Payout ratiopays out more than its earnings 245.7% 94 Market momentumstrong62
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) +11.18% 76 Relative strength (6 months) +9.56% 63 1-year return +12.02% 48 Distance from 200-day average +7.06% 61 Riskvery low19
How much the price swings.
Metric Value Position in group Volatility (60 days) 20.2% 10 Beta (1 year) 0.27 30 Maximum drawdown (12 months) 17.1% 16
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Pfizer is priced as in the past and in line with similar companies
On the latest fiscal year's earnings (2025), Pfizer's P/E today is 21.2, in line with the median of its last 10 fiscal years (18.6; between 9.37 and 77.8 from 2016 to 2025). Pfizer's P/E (trailing 12 months): 41.3, in line with the median of a group of 10 similar companies (42.3).
Compared with 10 similar companies
| Metric | Pfizer | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 41.3 | Middle | |
| Forward P/E | 9.80 | Low | |
| Operating margin | 29.1% | Middle | |
| ROE | 4.5% | Low | |
| Debt/equity | 0.71 | Middle |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Pfizer. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
$16.58B
Latest quarter · Q3 2026
Net income
$3.24B
Latest quarter · Q3 2026
Quarterly net margin
19.6%
Latest quarter · Q3 2026
Numbers and valuation
Full valuation- Market cap
- $164.67B
- P/E
- 41.3
- EPS
- $0.70
- Volume
- 21.45M
- Daily trading
- €951.54M
- Dividend yield
- 5.95%
- Last ex-dividend on November 6, 2026
How Pfizer is changing
All resultsRevenue grew 8.5% a year on average over the last 5 years
Operating margin fell from 39.4% to 30.6%
Profits turn into cash: free cash flow equal to 132% of net income
Returns
Pfizer returns with dividends
$1,000 invested in Pfizer 5 years ago, on November 15, 2021, would be worth $763 today with dividends reinvested: −23.69% in total, −5.27% per year. On price alone it would be $582 (−41.81%).
| Period | Pfizer | S&P 500 | $1,000 becomes |
|---|---|---|---|
| 1 month | +1.83% | −3.12% | $1,018 |
| 6 months | +11.29% | +1.58% | $1,113 |
| Year to date | +16.02% | +10.46% | $1,160 |
| 1 year | +19.56% | +12.23% | $1,196 |
| 3 years | +21.08% | +71.41% | $1,211 |
| 5 years | −23.69% | +61.48% | $763 |
| 10 years | +49.01% | +249.40% | $1,490 |
Over the last 6 months it has done better than 38% of the stocks in the Healthcare sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. S&P 500: price only. Calculate your investment
The chart in detail
Pfizer: technical analysis
Pfizer is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 52.8% below its highest close since January 2, 1990 ($61.25, December 16, 2021).
- Trend
- Upward
- RSI (14 sessions)
- 45
- Between 30 and 70
- vs 200-session average
- +7.06%
Support and resistance
Price areas where Pfizer has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance$29.21+1.12%2 touches, last on October 28, 2026
- Last price$28.89
- Support$28.75−0.50%3 touches, last on November 6, 2026
- Support$27.80−3.77%6 touches, last on August 31, 2026
- Support$27.19−5.90%2 touches, last on October 5, 2026
Volatility and risk
Over the last year it has moved little with the S&P 500.
- Beta (1 year) vs S&P 500
- 0.27
- Volatility (60 sessions, annualised)
- 20.2%
- Largest fall in the last year
- −17.09%
Close of November 13, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Pfizer: seasonality
Average monthly price change over 37 years
Over the last 37 years, the strongest month for Pfizer has been November: +2.42% on average, positive in 25 years out of 36. The weakest has been February: −1.43% on average, positive in 15 years out of 37.
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | −0.03% | +0.14% | 18 of 36 |
| February | −1.43% | −1.26% | 15 of 37 |
| March | +1.28% | +1.20% | 22 of 37 |
| April | +1.43% | +1.10% | 21 of 37 |
| May | +1.14% | +0.88% | 20 of 37 |
| June | −0.61% | −0.98% | 17 of 37 |
| July | +1.62% | +1.04% | 19 of 37 |
| August | −0.08% | −0.54% | 18 of 37 |
| September | +0.37% | −0.24% | 18 of 37 |
| October | +2.13% | +1.70% | 25 of 37 |
| November | +2.42% | +3.23% | 25 of 36 |
| December | +1.05% | +0.06% | 18 of 36 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Pfizer and its competitors
Biopharmaceutical products form the core of the business, organized into three segments: Biopharma, PC1 and Pfizer Ignite. Internal medicine includes Eliquis for cardiovascular metabolic diseases, Nurtec ODT/Vydura and Zavzpret for migraine, the Prevnar family and Abrysvo among vaccines, and Paxlovid for COVID-19. Inflammation and immunology products include Xeljanz, Enbrel and Cibinqo, while rare disease treatments cover amyloidosis, hemophilia and endocrine diseases with the Vyndaqel family, Genotropin and BeneFIX.
- Headquarters
- New York, United States
- Employees
- 75,000
- Founded
- 1849
- Chief executive
- Albert Bourla
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| PfizerPFE | $164.67B | 29.1% | 41.3 | +11.29% |
| Gilead SciencesGILD | $208.48B | 38.2% | — | +26.33% |
| Bristol-Myers SquibbBMY | $129.66B | 32.4% | 14.1 | +12.48% |
| AmgenAMGN | $251.89B | 34.1% | 27.0 | +38.41% |
| MerckMRK | $364.26B | 35.2% | 147.8 | +30.24% |
| AbbVieABBV | $521.5B | 36.6% | 50.6 | +41.50% |
Same industry or related industries, similar size. Compare Pfizer with its competitors · Full profile
